---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-015159"
form_type: "8-K"
ticker: "CTNM"
cik: "0001855175"
company_name: "Contineum Therapeutics, Inc."
filed_at: "2026-03-05T23:59:59+00:00"
generated_at: "2026-05-15T19:52:30.853612+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Contineum reports Q4 2025 net loss of $15.2M; upsizes ATM to $100M; Phase 2 IPF trial dosed

## Summary
- Net loss of $15.2M vs $14.6M in Q4 2024; R&D expenses $12.8M, G&A $4.4M.
- Cash and equivalents $262.9M; cash runway projected through mid-2029.
- Initiated dosing in PROPEL-IPF Phase 2 trial of PIPE-791 for IPF (324 patients).
- Amended ATM sales agreement to offer up to $100M in common stock; lock-up until March 11, 2026.
- Topline data from PIPE-791 Phase 1b chronic pain trial expected Q2 2026; J&J Phase 2 MDD trial recruiting.

## SEC filing metadata
- accession: 0001628280-26-015159
- form_type: 8-K
- ticker: CTNM
- cik: 0001855175
- company_name: Contineum Therapeutics, Inc.
- filed_at: 2026-03-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855175/000162828026015159/0001628280-26-015159-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855175/000162828026015159/ctnm-20260305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-015159
- JSON: https://secwatch.observer/filing/0001628280-26-015159.json
- Plain text: https://secwatch.observer/filing/0001628280-26-015159.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.